The catalog of compounds for use in psychedelic drug research continues to grow.
The researchers hope these compounds “will expand the universe of options for improving mental health.”
Surprisingly, 4-HO-TMT has binding affinity similar to psilocin at 5-HT2A.
Psychedelic Science Review Editor Barb Bauer conducts a review of some landmark studies.
This structural analog of DMT is an understudied compound presenting new options for psychedelic drug development.
Using psychedelics to treat chronic pain is understudied yet full of potential.
Three doses of fluoxetine were needed to elicit the effects of one dose of noribogaine.
This is the first preclinical study to examine the anti-depressive effects of ibogaine and noribogaine.
Understanding the structure of this synthetic analog of 5-MeO-DMT may help explain the effects of naturally occurring chemical cocktails.
New crystalline forms of norpsilocin create new options for developing psychedelic drug formulations.